Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
- Sponsor
- University Hospital, Bordeaux
- Study ID
- NCT06780553
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cholangiocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Proteomic profiling — DIAGNOSTIC_TESTProteomic profiling as a diagnostic tool in the face of suspected extrahepatic cholangiocarcinoma stenosis
Study Details
The study aims to valide a proof of a concept of the proteomic profiling as a diagnostic tool for bile duct stenosis suspicious of cholangiocarcinoma. The main objective is to evaluate the addition of proteomic profiling to the conventional histological diagnosis of endo-biliary cytological sampling of biliary stenosis, compared with cytological sampling alone. With the addition of proteomic profiling to the conventional histological diagnostic technique, an overall diagnostic sensitivity of 80% is expected
Key Dates
- First listed
- Jan 17, 2025
- Start date
- Nov 30, 2025
- Status verified
- Jun 2025
- Primary completion
- Mar 31, 2026
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 60 participants (estimated)
Arms
- Arm: Suspected cholangiocarcinomaPatient with biliary stenosis of undetermined origin who has had an endo-biliary cytological sample (biopsy and/or brushing) for suspected cholangiocarcinoma
Primary Outcome Measure
Sensitivity of the proteomic profiling [ Time Frame: Baseline ]
Related Studies
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Biobank for Cholestatic Liver Diseases.Recruiting · Mayo Clinic · Rochester, Minnesota
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid TumoursPHASE1/PHASE2 · Recruiting · Bold Therapeutics, Inc. · Santa Monica, California